Back To: Home : Featured Technology : Assay Development

CLICK HERE FOR WHAT'S NEW IN:
 

Asuragen enters oncology collaboration with Merck
November 2007
SHARING OPTIONS:

AUSTIN, Texas—Asuragen Pharmacogenomic Services, a division of Asuragen Inc., recently entered into a research collaboration with Merck & Co. Inc. to develop a biomarker and pharmacogenomic test for cancer clinical trials.  Under the terms of the agreement, Asuragen will apply the information gained from an expression signature identified by Merck's oncology research program to the development of a diagnostic assay for use in Merck's cancer clinical trials and to potentially form the basis for commercial companion diagnostic tests for oncology therapies. Asuragen will receive an undisclosed payment for the development of the test, which is expected to be completed in 2008. Upon completion of assay development and validation, Asuragen will be eligible for additional payments associated with successful transfer of the diagnostic assays to clinical reference laboratories.
 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.